The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...
A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...
The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...
DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...
Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...
San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...